Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Why now
Thesis: Cash for pipeline at cost of dilution
Catalyst to watch: Trial data readouts from funded programs
Main risk: Dilution and convert pressure on shares
Why it matters
Raising $575M via stock and converts funds trials but dilutes equity holders and adds leverage.
Details
Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the...
Sources
- prnewswire · 2026-09-28 20:30 UTC